Celcuity's Revtorpyk wins FDA approval but won't launch until late Q3, sending shares down 14% as analysts expected a faster rollout.
July 17, 2026 02:03 PM EDTUpdated July 20, 06:35 AM
Celcuity got its cancer drug approved. Then its stock dipped
The FDA’s approval for Celcuity’s cancer drug Revtorpyk on Tuesday was widely anticipated. What Wall Street didn’t expect was that the drug …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s…
Celcuity's Revtorpyk wins FDA approval for use in HR+/HER2- breast cancer without a PIK3CA mutation.
Celcuity stock crashed Tuesday on disappointing results for its three-drug approach to advanced breast cancer.
Celcuity's breast cancer drug received approval from the Food and Drug Administration. "Clecuity Gets FDA Approval for Breast…
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a…
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results…
Celcuity gains FDA approval for closely watched breast cancer drug
Correction to Celcuity Gets FDA Approval Headline
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer
Why Legend Biotech stock fell 10% despite record Carvykti sales
Celcuity's breast cancer drug approved, its first
FDA approves breast cancer drug that cut progression risk by 76%
